Scarica l'app Stockscreener
3.445
2.37%
0.065
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.38
Aprire:
$3.37
Volume 24 ore:
398.74K
Relative Volume:
0.68
Capitalizzazione di mercato:
$80.70M
Reddito:
$160.43M
Utile/perdita netta:
$-227.64M
Rapporto P/E:
-0.0501
EPS:
-68.77
Flusso di cassa netto:
$-170.79M
1 W Prestazione:
+17.29%
1M Prestazione:
+94.38%
6M Prestazione:
+24.91%
1 anno Prestazione:
-67.66%
Intervallo 1D:
$3.30
$3.56
Intervallo di 1 settimana:
$2.83
$4.0597
Portata 52W:
$1.38
$19.69
Agenus Inc Stock (AGEN) Company Profile
Nome
Agenus Inc
Settore
Industria
Telefono
781-674-4410
Indirizzo
3 FORBES ROAD, LEXINGTON, MA
Confronta AGEN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AGEN
Agenus Inc
|
3.465 | 80.70M | 160.43M | -227.64M | -170.79M | -68.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
418.21 | 115.57B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.14 | 60.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
534.38 | 37.56B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
263.63 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
221.82 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Agenus Inc Stock (AGEN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-07-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-07-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-07-18 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-06-06 | Iniziato | Robert W. Baird | Outperform |
| 2023-02-28 | Ripresa | H.C. Wainwright | Buy |
| 2022-09-28 | Iniziato | SMBC Nikko | Outperform |
| 2021-12-16 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-19 | Ripresa | B. Riley FBR | Buy |
| 2019-04-22 | Iniziato | B. Riley FBR | Buy |
| 2016-10-28 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2016-10-27 | Reiterato | Maxim Group | Buy |
| 2016-03-11 | Aggiornamento | Maxim Group | Hold → Buy |
| 2015-12-16 | Iniziato | Jefferies | Buy |
| 2015-10-27 | Downgrade | Maxim Group | Buy → Hold |
| 2015-07-27 | Reiterato | MLV & Co | Buy |
| 2015-06-11 | Iniziato | Oppenheimer | Outperform |
| 2015-01-12 | Reiterato | Maxim Group | Buy |
| 2015-01-09 | Reiterato | MLV & Co | Buy |
| 2015-01-09 | Reiterato | Maxim Group | Buy |
| 2014-12-19 | Reiterato | Maxim Group | Buy |
| 2014-05-08 | Reiterato | Maxim Group | Buy |
| 2014-03-14 | Reiterato | MLV & Co | Buy |
| 2013-10-08 | Reiterato | Maxim Group | Buy |
| 2012-01-05 | Iniziato | William Blair | Outperform |
| 2011-12-01 | Iniziato | Global Hunter Securities | Buy |
Mostra tutto
Agenus Inc Borsa (AGEN) Ultime notizie
Peptide Cancer Vaccine Market Set to Witness Significant Growth - openPR.com
Agenus (AGEN) Registers Plan to Offer 165,000 Common Shares | AG - GuruFocus
Analyst Reiterates Neutral Rating for Agenus (AGEN) | AGEN Stock News - GuruFocus
Agenus (AGEN) Target Price Raised by Analyst Baird | AGEN Stock News - GuruFocus
Agenus (AGEN) Receives Price Target Increase from Baird | AGEN S - GuruFocus
Agenus Inc. (NASDAQ:AGEN) Q1 2025 Earnings Call Transcript - Insider Monkey
Agenus names Dr Richard Goldberg as CDO - Medical Buyer
Agenus Inc (AGEN) Q1 2025 Earnings Call Highlights: Strategic Moves and Financial Challenges - Yahoo Finance
Agenus Inc (AGEN) Q1 2025 Earnings Call Highlights: Strategic Mo - GuruFocus
Agenus Inc. Reports Q1 2025 Progress and Financials - TipRanks
Agenus Inc. Earnings Call: Optimism Amid Challenges - TipRanks
Agenus signals near-term strategic transactions and operational cash burn target below $50M amid BOT/BAL data advances - MSN
Agenus (AGEN) Moves to Sell 165,000 Shares of Common Stock - GuruFocus
Agenus: Q1 Earnings Snapshot - MySA
Agenus appoints oncology veteran Dr. Goldberg as CDO By Investing.com - Investing.com Canada
Agenus (AGEN) Sets Strategic Path with New Leadership and Transactions - GuruFocus
Transcript : Agenus Inc., Q1 2025 Earnings Call, May 12, 2025 - marketscreener.com
Agenus reports Q1 EPS ($1.03), consensus ($1.98) - TipRanks
Earnings call transcript: Agenus reports Q1 2025 net loss, stock rises premarket - Investing.com
Agenus (AGEN) Reports Strong Q1 Revenue Surpassing Expectations - GuruFocus
Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer | AGEN Stock News - GuruFocus
Agenus (AGEN) Reports Q1 Earnings, Beats EPS Estimates - GuruFocus
Agenus Inc (AGEN) Q1 2025 Earnings: EPS Beats Estimates at -$1.0 - GuruFocus
Agenus Reports Q1 2025 Financial Results and Key Business Updates | AGEN Stock News - GuruFocus
AGEN Welcomes Renowned Cancer Expert Dr. Richard Goldberg as Chi - GuruFocus
Dr. Richard Goldberg Joins Agenus as Chief Development Officer - citybiz
Renowned Gi Oncology Leader Dr. Richard Goldberg Joins Agenus As Chief Development Officer - marketscreener.com
Agenus Reports Q1 2025 Financial Results and Key Business Updates - Stock Titan
Agenus appoints oncology veteran Dr. Goldberg as CDO - Investing.com
Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer - Eagle-Tribune
Agenus Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before November 5, 2024 to Discuss Your RightsAGEN - ACCESS Newswire
Agenus (AGEN) Set for Q1 Earnings Release with Optimistic EPS Re - GuruFocus
Agenus Inc (AGEN) Q1 2025: Everything You Need To Know Ahead Of Earnings - GuruFocus
Agenus (AGEN) Set for Q1 Earnings Release with Optimistic EPS Revisions - GuruFocus
Lost Money on Agenus Inc. (AGEN)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
Investors Who Lost Money on Agenus Inc. (AGEN) Should Contact Levi & Korsinsky About Pending Class ActionAGEN - ACCESS Newswire
Peptide Cancer Vaccine Market Is Booming Worldwide | Marker - openPR.com
Agenus (AGEN) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance
Agenus to Provide Corporate Update and First Quarter 2025 Financial Report | AGEN Stock News - GuruFocus
Agenus To Provide Corporate Update And First Quarter 2025 Financial Report - marketscreener.com
Agenus to Reveal Q1 2025 Financial Performance and Strategic Updates: Key Details for Investors - Stock Titan
Agenus to Provide Corporate Update and First Quarter 2025 Financial Report - Bluefield Daily Telegraph
Agenus' BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Stu - GuruFocus
Breakthrough: Agenus BOT/BAL Cancer Treatment Achieves 90% Response Rate Across Multiple Tumors - Stock Titan
AGEN Investors Have Opportunity to Lead Agenus Inc. Securities Fraud Lawsuit - marketscreener.com
Press Release Distribution & PR Platform - ACCESS Newswire
Agenus Inc Azioni (AGEN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):